JOHNSON & Johnson sales
decreased 0.2% year-on-year in the
first quarter of 2012 to US$16.1
billion, whilst the company also
posted net earnings for the period
of US$3.9 billion.
First quarter 2012 net earnings
included an after-tax gain of
US$106 million which has been
attributed to the currency
adjustment associated with the
planned acquisition of Synthes.
Meanwhile the company also
updated its earnings guidance for
full-year 2012 to between US$5.07
and US$5.17 per share, which
reflects the positive impact of
current exchange rates.
"We continue to bring meaningful
innovations to our patients and
customers through the strong
performance of our recently
launched products," said J&J CEO
and Chairman William Weldon.
“The dedication of the people of
Johnson & Johnson gives me great
confidence in the prospects of our
business to deliver sustainable
growth, well into the future,” he
added.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.